EICHORPublic-registry site landscape for NCT07673107, “Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor”, a Upper Limb Essential Tremor study sponsored by AbbVie. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07673107 (registry record) |
| Study title | Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor |
| Official title | A Phase 2b Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of AGN-151607-DP (USAN: gemibotulinumtoxinA) for the Treatment of Upper Limb Essential Tremor in Adults |
| Sponsor | AbbVie |
| Condition(s) | Upper Limb Essential Tremor |
| Phase | PHASE2 |
| Listed sites | 3 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT07673107.
Eichor generates a preliminary site-risk snapshot for NCT07673107 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
More from AbbVie
← Eichor home · All tracked trials · Upper Limb Essential Tremor studies · Weekly briefs
